Skip to main content
. Author manuscript; available in PMC: 2016 Jun 1.
Published in final edited form as: J Thromb Haemost. 2015 Apr 23;13(6):1064–1072. doi: 10.1111/jth.12901

Fig. 5.

Fig. 5

Plasma ADAMTS13 activity in patients with hyperbilirubinemia before and after bilirubin oxidase treatment. A. Plasma ADAMTS13 activity in patients with elevated serum levels of unconjugated bilirubin determined by the cleavage of F485-rVWF73-H and D633-rVWF73-H as indicated. An unpaired student t-test was performed to demonstrate that the difference is statistically highly significant, p<0.001. B and C are plasma ADAMTS13 activity before and after being treated with bilirubin oxidase (2 U/ml) that was determined by the cleavage of F485-rVWF73-H and D633-rVWF73-H, respectively. Paired student t-test was performed to demonstrate the difference before and after bilirubin oxidase treatment was not statistically significant in B, but highly significant in C with p<0.001. D and E show the linear correlations between the net increase of plasma ADAMTS13 activity after being treated with bilirubin oxidase and serum bilirubin concentrations determined by D633-rVWF73-H (r2=0.49) and by F485-rVWF73-H (r2=0.002), respectively.